43 results about "Treatment failure" patented technology

Data processing methods facilitate an exchange, between healthcare providers and patients or other users, of structured data for objective health signs and subjective symptoms from the patient or caregiver during a pre-visit and/or follow-up period of care; standardized data-informed Loop protocols for following health conditions; data-informed ARC OF RECOVERY profiles that represent population-based recovery standards for signs, symptoms, or composites; automated alerts, based on analytics or machine learning, to warn health care providers regarding impending treatment failures or worsening of conditions. Patients in pre-visit or follow-up stages of healthcare respond to questions structured by a provider for objective signs and subjective symptoms, and may view questions and responses with associated alerts or status updates in a consolidated display that provides patient graphic images and comments about conditions. Aspects of pre-visit or follow-up care are Tracker historical graphical displays for evaluation by the physician against expected profiles, protocols or other standards.

A method, system and computer readable medium of: providing feature data of at least one organ at risk or target volume of said patient from a database of non-transitory data stored on a data storage device of prior patients data; generating, using a data processor, a distribution of dose points of the at least one organ at risk or target volume of said patient based on said feature data; calculating, using the data processor, at least one of (i) a probability of toxicity for the at least one organ at risk or (ii) a probability of treatment failure for the at least one target volume, based on said distribution of dose points; assessing, using the data processor, a dosimetric-outcome relationship based on the calculated probability; and automatically formulating, using the data processor, a treatment plan using the dosimetric-outcome relationship to minimize the at least one treatment-related risk.

The present invention is directed to the administration of an HSV derived oncolytic virus and a PI3K/AKT/mTOR pathway inhibitor to treat various types of resistant tumors. Therapy-resistant tumor formation is one of the main causes for treatment failure in the clinic. The treatment methods and compositions disclosed herein sensitize resistant tumors to the treatment of herpes simplex virus (HSV)-based oncolytic virotherapy. Pre or co-treatment of resistant tumor cells with the mTOR inhibitor, rapamycin, or certain PI3K inhibitors, such as LY294002, can efficiently sensitize the tumors to HSV derived oncolytic viruses, whereby the replication and spread of the viruses are dramatically enhanced.

It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequency, enabling treatment of high-titer infections without treatment failure due to spontaneous resistance. Accordingly, certain embodiments provide composition comprising a rifamycin and a switch region inhibitor, as well as methods of use thereof.

The invention relates to two VEGF receptor fusion proteins, a preparation method thereof and the application in treating eye diseases, wherein, the eye diseases comprise age-retinal pigment epitheliitis, diabetic retinopathy, diabetic xanthelasma gland and treatment failure caused by neovascularization growth, such as laser photocoagulation body and surgery retina transplantation.

The present invention provides methods for treating individuals having an HCV infection, which individuals have failed to respond to therapy with an INF-α other than consensus interferon (CIFN), or who, following cessation of therapy with an INF-α other than CIFN, have suffered relapse. The methods generally involve a dosage regimen involving administering a dose of CIFN and a dose of ribavirin for a period of time, where the dosage regimen is effective to achieve a sustained viral response in the individual.

MRSA CC398 is a clone of S. aureus that has recently emerged in pigs and other domestic animals worldwide. As any other MRSA, the clone displays high levels of antibiotic resistance and poses a serious threat to human health because of the risk of antibiotic treatment failure in human patients. We developed a new diagnostic test for identification of MRSA CC398 using a single one-step PCR that is very easily performed within a few hours. The test is based on the principle that clonal differences within S. aureus are reflected in the sequence of a gene (sau1hsdS1) located on the chromosome of this bacterial species. Accordingly, such a gene represents an optimal target for S. aureus and MRSA identification at the clone level. The test includes detection of the gene conferring methicillin resistance (mecA), therefore allowing rapid discrimination between methicillin-susceptible and methicillin-resistant variants of the clone. A preliminary validation of the test was performed on a collection of CC398 and non-CC398 strains, resulting in 100% sensitivity and 100% specificity. The test can be combined to real-time PCR technology to further reduce simplify the test performance as well as to allow quantification of the target MRSA clone in biological specimens. The invention has important applications related to surveillance and control of MRSA CC398 in humans, animals and food products.

The invention relates to a one-step method preparation process of treatment type drug resistant AIDS (acquired immunodeficiency syndrome) autologous plasma virus inactivated vaccine. Through blood collection, plasma separation and plasma virus inactivation, the vaccine is directly prepared; then, intravenous vaccination is performed; the whole process is completed in a sealed disposable consumable; the pollution risk in the preparation process can be effectively avoided; the vaccine preparation safety is ensured. The preparation process is simple; the cost is low; the inoculation procedure canalso be simplified; the technical requirements of large-dose (600 to 800ml) plasma virus inactivated vaccine inoculation are met. More importantly, the virus strain of the inactivated vaccine is froma patient self; the plasma is also from the patient self; the obvious safety, effectiveness and feasibility are realized. The principle of medical ethics is conformed; the problem of animal model lack of AIDS vaccine development can also be solved. The vaccine is applicable to the continuous treatment of AIDS patients with drug resistance and treatment failure, initial and conventional treatmenton AIDS patients without drug resistance, and emergent blockade treatment on occupational exposure persons.

The invention discloses a compound mequindox soluble powder for animals and a preparation method thereof, which aims to provide the compound mequindox soluble powder for the animals and the preparation method, wherein, the compound mequindox soluble powder for the animals can treat the complex infection of shigella shigae and colon bacillus of pigs, is quick to take effect, can solve the treatment failure phenomenon caused by feeding and drinking conditions of the pigs during the illness, and improve the rate of liveweight growth; and the preparation method has a simple process and is easy to realize. The powder comprises the compositions in percentage by weight: 2 to 10 percent of mequindox, 0.5 to 5 percent of colistin sulfate, 6 to 30 percent of sodium salicylate, and the balance being oral glucose. The soluble powder is a compound preparation formed by a double antimicrobial drug combined with a suspending agent, has quick effect on the complex infection of the shigella shigae and the colon bacillus of the pigs due to the fact that the mequindox and the colistin sulfate are jointly used, is effective and highly efficient, can solve the treatment failure phenomenon caused by feeding and drinking problems during the illness, accelerate the recovery of the pigs, and increase the weight of the pigs.

A system (100) includes an imaging system (130), and a therapy control device (122). The imaging system (130) generates temperature maps (140) and strain maps (142) of localized tissues of a patient. The therapy control device (122) includes one or more computer processors configured to detect at least one failure mode (300, 302, 304, 400) of generated mild hyperthermia in the localized tissues of the patient according to at least one of the temperature maps, the strain maps, or a signal indicative of detected inertial cavitation. In some embodiments, the therapy control device either halts therapy or issues a warning.

The invention relates to a diagnostic kit for fast determining aphis gossypii glover sensitivity to acetamiprid. The diagnostic kit comprises a finger-type pipe, an agent film and a filler. The finger-type pipe is a glass pipe with one enclosed end. The agent film is an acetamiprid agent film uniformly adhering to the inner surface of the finger-type pipe. The opening end of the finger-type pipe is detachably filled with the filler. The diagnostic kit is used for fast diagnosis of field aphis gossypii glover sensitivity to acetamiprid, shortens diagnosis time, produces accurate and reliable results and prevents adverse results such as cost increasing, prevention and treatment failure and environment pollution caused by use of acetamiprid in a resistant population.

The invention relates to the technical field of medical appliances, in particular to an instrument for the needle-picking therapy for lumbar, neck and shoulder diseases and a use method thereof. The instrument includes a needle body, the part, near the needle tip, of the needle body is provided with a slip stitch groove, and the part, near the needle end, of the needle body is like a flat notch. The use method of the instrument includes the following steps that 1, an adjustment needle rod does not need to be used, and people hold the flat notch of the needle body to make the needle tip pass through the ill skin of the waist, the neck and the shoulder until a disease source enters the slip stitch groove; 2, the needle tip vertically pick up the ill skin through force from the wrist, and blades cut off the ill skin from the root; 3, if the adjustment needle rod needs to be used, the adjustment needle rod is fixedly connected with a connection part, and the step 1 and the step 2 are repeated. In the pick-up process, the treatment failure rate caused by slippage of the disease source can be largely reduced, and the needle body can be used independently and can be connected with the adjustment needle rod for use in cooperation according to different locations of the ill skin of a patient.

The invention discloses an electrical impedance detection and online treatment device and method for flowing thrombus, and the device comprises a device housing, the top of the front surface of the device housing is fixedly provided with a touch liquid crystal screen, the middle part of the front surface of the device housing is provided with a packaging groove, and the interior of the packaging groove is provided with an operation panel in a packaging manner. A moving mechanism is installed between the operation panel and the equipment shell, an equipment cavity is formed in the bottom of the front face of the equipment shell, and a control circuit board and an EIST sensor are fixedly installed in the equipment cavity. According to the invention, the blood state in the extracorporeal circulation system can be accurately detected; the size, the number and the position information of flowing thrombus in the extracorporeal circulation system on the cross section of the circulation pipeline can be accurately detected. The blood environment in the circulation pipeline can be controlled, the detected information is used for controlling the administration dosage of the anticoagulant, the administration dosage can be automatically regulated and controlled, and damage to a patient caused by excessive administration or treatment failure caused by insufficient administration can be relieved.

The present invention provides methods for treating individuals having a hepatitis C virus (HCV) infection, which individuals have failed to respond to therapy with an IFN-α other than consensus interferon (CIFN), or who, following cessation of therapy with an IFN-α other than CIFN, have suffered relapse. The methods generally involve a treatment regimen comprising administering a first dosing regimen of CIFN, followed by a second dosing regimen of CIFN. Ribavirin is administered with at least the second dosing regimen.

The present invention provides a method of treatment failure packets, network device and processor, relates to a field of a computer, the packet in a cache has failed, indicating that the message has failed to the invention, and discard invalid packets to avoid the influence of the system reset or will fail to process the data as normal data brought to improve the reliability of the system. The methods are: by computer memory cache settings packets corresponding signs of poisoning, and the network device receives the packet, the packet will fail the corresponding cache poisoning where the identity is set to indicate intoxication, and failure messages where the cache rewrite, then indicates that the cache is empty. The invention is used for processing a packet failure.

An emergency treatment quality evaluation management system comprises a patient registration system, an emergency treatment system, a data acquisition system, a data processing system and a managementevaluation system. The patient registration system is used for collecting basic identity information of a patient; the emergency treatment system is used for recording treatment first-aid informationof the patient, wherein the treatment first-aid information comprises disease information, treatment duration information and treatment result information of the patient; the data processing system comprises a data classification module, a data proofreading module, a data analysis module and a data evaluation summary sheet; and the management evaluation system comprises a data query module, a statistics module, a case classification module and a key case storage module. According to the system, not only can the treatment process of the disease be analyzed and evaluated, but also treatment failure cases can be analyzed, and thus the overall treatment success rate is improved.

The invention provides an application of kosteletzkya virginica to preparation of a traditional Chinese medicine preparation for preventing and treating coxey, and further provides a kosteletzkya virginica traditional Chinese medicine composite composition for preventing and treating coxey and an application of the kosteletzkya virginica traditional Chinese medicine composite composition. The composition is prepared from the following raw materials in parts by mass of 40-50 parts of kosteletzkya virginica, 25-30 parts of spartina alterniflora, 8-12 parts of sweet wormwood herbs, 8-12 parts ofbrucea amarissima, and 4-6 parts of radix scutellariae. The traditional Chinese medicine composite composition can effectively prevent and treat coxey. The composite plant extract preparation can prevent problems of reverse tolerance and the like, so that the probability of prevention and treatment failure can be greatly reduced. The composition is a purely plant extract compound recipe, and is low in remaining in bodies of chickens, and favorable in biological safety.

The invention relates to an application of an ERK micro-molecular inhibitor in the preparation of drugs for inhibiting drug-resistant lung cancer cells. The ERK micro-molecular inhibitor inhibits the phosphorylation level of ERK kinase, prevents cell autophagy, and substantially inhibits generation of gefitinib-resistant lung cancer cells in vivo and in vitro, and the ERK micro-molecular inhibitor is TIC10. The lung cancer drug-resistant cell proliferation inhibition molecular mechanism of the ERK micro-molecular inhibitor TIC10 is explicated in the invention, the in-vitro and in-vitro drug-resistant lung cancer cell treatment effect of the ERK micro-molecular inhibitor TIC10 is researched on the basis of the molecular mechanism, and the ERK micro-molecular inhibitor TIC10 can be used for preparing drugs for inhibiting drug-resistant lung cancer cells, solves the problem of treatment failure caused by resistance of lung cancer cells to targeting drugs, reduces the generation of the drug-resistant lung cancer cells, and prolongs the life of lung cancer patients.